Search Page

1

Cite

Share

NHLBI clinical trials workshop: an executive summary.

Zheng G, Wu CO, Yang S, Waclawiw MA, DeMets DL, Geller NL. Zheng G, et al. Among authors: geller nl. Stat Med. 2012 Nov 10;31(25):2938-43. doi: 10.1002/sim.5406. Epub 2012 Jun 26. Stat Med. 2012. PMID: 22733431

Cite

Share

2

Cite

Share

The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.

Buyse M, George SL, Evans S, Geller NL, Ranstam J, Scherrer B, Lesaffre E, Murray G, Edler L, Hutton J, Colton T, Lachenbruch P, Verma BL. Buyse M, et al. Among authors: geller nl. Stat Med. 1999 Dec 30;18(24):3435-51. doi: 10.1002/(sici)1097-0258(19991230)18:24<3435::aid-sim365>3.0.co;2-o. Stat Med. 1999. PMID: 10611617

Cite

Share

3

Cite

Share

Surrogate endpoints in randomized cardiovascular clinical trials.

Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Domanski M, et al. Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Fundam Clin Pharmacol. 2011. PMID: 20698890 Review.

Cite

Share

4

Cite

Share

Longitudinal clinical trials with adaptive choice of follow-up time.

Jeffries N, Geller NL. Jeffries N, et al. Among authors: geller nl. Biometrics. 2015 Jun;71(2):469-77. doi: 10.1111/biom.12287. Epub 2015 Mar 27. Biometrics. 2015. PMID: 25818116 Free PMC article.

Cite

Share

5

Cite

Share

Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH. Joo J, et al. Among authors: geller nl. Clin Trials. 2010 Oct;7(5):597-604. doi: 10.1177/1740774510381285. Epub 2010 Aug 6. Clin Trials. 2010. PMID: 20693186 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Limited access data sets from studies funded by the National Heart, Lung, and Blood Institute.

Geller NL, Sorlie P, Coady S, Fleg J, Friedman L. Geller NL, et al. Clin Trials. 2004;1(6):517-24. doi: 10.1191/1740774504cn050oa. Clin Trials. 2004. PMID: 16279292

Cite

Share

7

Cite

Share

Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.

Ganesh SK, Skelding KA, Mehta L, O'Neill K, Joo J, Zheng G, Goldstein J, Simari R, Billings E, Geller NL, Holmes D, O'Neill WW, Nabel EG. Ganesh SK, et al. Among authors: geller nl. Pharmacogenomics. 2004 Oct;5(7):952-1004. doi: 10.1517/14622416.5.7.949. Pharmacogenomics. 2004. PMID: 15469413

Cite

Share

8

Cite

Share

Smart Technology in Lung Disease Clinical Trials.

Geller NL, Kim DY, Tian X. Geller NL, et al. Chest. 2016 Jan;149(1):22-6. doi: 10.1378/chest.15-1314. Epub 2016 Jan 6. Chest. 2016. PMID: 26135330 Free PMC article.

Cite

Share

9

Cite

Share

The future of clinical trials: A panel discussion.

D'Agostino R Sr, DeMets D, Friedewald W, Goodman S, Witte J, Geller NL. D'Agostino R Sr, et al. Among authors: geller nl. Stat Med. 2012 Nov 10;31(25):3068-72. doi: 10.1002/sim.5484. Epub 2012 Jul 16. Stat Med. 2012. PMID: 22806631 Free PMC article.

Cite

Share

10

Cite

Share

Detecting treatment differences in group sequential longitudinal studies with covariate adjustment.

Jeffries NO, Troendle JF, Geller NL. Jeffries NO, et al. Among authors: geller nl. Biometrics. 2018 Sep;74(3):1072-1081. doi: 10.1111/biom.12837. Epub 2017 Dec 18. Biometrics. 2018. PMID: 29265179 Free PMC article.

Cite

Share